Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Targeting Phosphatidylserine in Anti-Cancer Therapy

Author(s): Heidi Kenis and Chris Reutelingsperger

Volume 15, Issue 23, 2009

Page: [2719 - 2723] Pages: 5

DOI: 10.2174/138161209788923903

Price: $65

Abstract

Targeted delivery of cytotoxic agents limits the severe toxic side-effects of anti-cancer drugs on healthy tissues. Annexin A5 is a well explored probe to target phosphatidylserine (PS)-expressing cells in vivo. Our novel understanding of the cellular and molecular mechanism of annexin A5 as a cell-entry agent and the finding that PS is expressed on living tumour as well as endothelial cells in the tumour vasculature, will allow the development of lead compounds for anticancer therapy.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy